Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Cardiol Therapeutics (CRDL)

Cardiol Therapeutics (CRDL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 146,966
  • Shares Outstanding, K 68,998
  • Annual Sales, $ 0 K
  • Annual Income, $ -20,840 K
  • 60-Month Beta 0.91
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 9.55
Trade CRDL with:

Options Overview Details

View History
  • Implied Volatility 100.18% ( -0.36%)
  • Historical Volatility 107.10%
  • IV Percentile 9%
  • IV Rank 3.93%
  • IV High 1,073.57% on 10/03/23
  • IV Low 60.32% on 06/04/24
  • Put/Call Vol Ratio 0.06
  • Today's Volume 109
  • Volume Avg (30-Day) 264
  • Put/Call OI Ratio 0.01
  • Today's Open Interest 12,877
  • Open Int (30-Day) 14,276

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate -0.09
  • Number of Estimates 2
  • High Estimate -0.09
  • Low Estimate -0.09
  • Prior Year -0.09
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.70 +29.12%
on 06/20/24
2.52 -12.90%
on 06/17/24
-0.22 (-8.92%)
since 06/14/24
3-Month
1.55 +41.61%
on 04/19/24
3.12 -29.65%
on 06/12/24
+0.47 (+27.62%)
since 04/16/24
52-Week
0.66 +232.07%
on 10/23/23
3.12 -29.65%
on 06/12/24
+1.38 (+169.69%)
since 07/14/23

Most Recent Stories

More News
5 Biotech Stocks Under $10 With Multibagger Potential

As the biotech industry continues to redefine the healthcare landscape, here are five penny biotech stocks poised for meteoric growth in this evolving industry.

ADCT : 3.94 (-1.75%)
$SPX : 5,660.75 (+0.52%)
RZLT : 4.72 (-2.68%)
TRVI : 2.88 (+1.05%)
ELEV : 3.03 (+0.33%)
CRDL : 2.20 (+3.05%)
Cardiol Therapeutics Reports Results of 2024 Annual General and Special Meeting of Shareholders

Toronto, Ontario--(Newsfile Corp. - June 27, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and...

CRDL : 2.20 (+3.05%)
CRDL.TO : 3.00 (+4.17%)
Cardiol Therapeutics to Webcast Virtual Annual General and Special Meeting of Shareholders on June 26th at 4:30 p.m. EDT

Toronto, Ontario--(Newsfile Corp. - June 25, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and...

CRDL : 2.20 (+3.05%)
CRDL.TO : 3.00 (+4.17%)
Cardiol Therapeutics Announces Positive Topline Data from its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent Pericarditis

Administration of CardiolRx™ led to a marked reduction in the primary efficacy endpoint of pericarditis painCardiolRx™ also shown to reduce inflammation in patients with elevated CRP89% of patients...

CRDL : 2.20 (+3.05%)
CRDL.TO : 3.00 (+4.17%)
Cardiol Therapeutics Announces Phase II ARCHER Trial Presented at the World Congress on Acute Heart Failure 2024

Scope of presentation included trial design, rationale, and blinded baseline data on first 50 patients randomized into the Phase II study evaluating CardiolRx™ in patients with acute myocarditis ARCHER...

CRDL : 2.20 (+3.05%)
CRDL.TO : 3.00 (+4.17%)
How a Recent M&A Deal Could Catapult a Small-Cap Biotech to New Heights

Cardiol Therapeutics (CRDL), a clinical-stage life sciences company, is researching and developing new drugs to fight inflammation and scarring in the heart. Their main drug, CardiolRx™, is b

NVO : 140.86 (-0.37%)
CRDL : 2.20 (+3.05%)
CRDL.TO : 3.00 (+4.17%)
Cardiol Therapeutics Announces Year-End 2023 Update on Operations

Completed patient enrollment in the Phase II MAvERIC-Pilot study evaluating CardiolRx™ in patients withrecurrent pericarditis, with topline results expected in Q2 2024CardiolRx™ granted U.S. FDA Orphan...

CRDL : 2.20 (+3.05%)
CRDL.TO : 3.00 (+4.17%)
Cardiol Therapeutics Completes Patient Enrollment in its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent Pericarditis

Topline Results Expected in Q2 2024This is a Designated News Release.Toronto, Ontario--(Newsfile Corp. - February 21, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"),...

CRDL : 2.20 (+3.05%)
CRDL.TO : 3.00 (+4.17%)
Cardiol Therapeutics Granted Orphan Drug Designation for its Lead Drug Candidate for the Treatment of Pericarditis

Designation Based on Pre-Clinical Data and Initial Clinical Data from the Company's MAvERIC-Pilot Phase II StudyThis is a Designated News Release.Toronto, Ontario--(Newsfile Corp. - February 15, 2024)...

CRDL : 2.20 (+3.05%)
CRDL.TO : 3.00 (+4.17%)
Cardiol Therapeutics Regains Compliance with all Applicable Listing Standards of The Nasdaq Capital Market

Toronto, Ontario--(Newsfile Corp. - January 24, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research...

CRDL : 2.20 (+3.05%)
CRDL.TO : 3.00 (+4.17%)

Business Summary

Cardiol Therapeutics Inc. is a clinical-stage biotechnology company. It focused on developing innovative anti-inflammatory therapies for the treatment of cardiovascular disease. The company's lead product consist CardiolRx(TM). Cardiol Therapeutics Inc. is based in Oakville, ON.

See More

Key Turning Points

3rd Resistance Point 2.30
2nd Resistance Point 2.24
1st Resistance Point 2.18
Last Price 2.20
1st Support Level 2.06
2nd Support Level 2.00
3rd Support Level 1.94

See More

52-Week High 3.12
Last Price 2.20
Fibonacci 61.8% 2.18
Fibonacci 50% 1.89
Fibonacci 38.2% 1.60
52-Week Low 0.66

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar